• By Sherri Oslick

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Takeda Pharmaceutical Co. et al. v. Accord Healthcare, Inc.
    1:11-cv-06360; filed September 12, 2011 in the Southern District of New York

    • Plaintiffs:  Takeda Pharmaceutical Co.; Takeda Pharmaceuticals North America, Inc.
    • Defendant:  Accord Healthcare, Inc.

    Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,329,404 (same title, issued December 11, 2001), 6,166,043 (same title, issued December 26, 2000), 6,172,090 (same title, issued January 9, 2001), 6,211,205 (same title, issued April 3, 2001), 6,271,243 (same title, issued August 7, 2001), and 6,303,640 (same title, issued October 16, 2001) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Takeda's Actos® (pioglitazone hydrochloride, used to treat type II diabetes).  View the complaint here.


    Novartis AG et al. v. Accord Healthcare, Inc. USA et al.

    1:11-cv-01631; filed September 9, 2011 in the District Court of the District of Columbia

    • Plaintiffs:  Novartis AG; Novartis Pharmaceuticals Corp.
    • Defendants:  Accord Healthcare, Inc. USA; Intas Pharmaceutical Ltd.

    Infringement of U.S. Patent Nos. 6,025,391 ("Enteric-Coated Pharmaceutical Compositions of Mycophenolate," issued February 15, 2000), 6,172,107 ("Entric-Coated Pharmaceutical Compositions," issued January 9, 2001), and 6,306,900 (same title, issued October 23, 2001) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Novartis' Myfortic® (mycophenolate sodium, used for the prophylaxis or prevention of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids).  View the complaint here.


    Abbott Laboratories et al. v. Hospira Inc.

    1:11-cv-00795; filed September 9, 2011 in the District Court of Delaware

    • Plaintiffs:  Abbott Laboratories; Wisconsin Alumni Research Foundation
    • Defendant:  Hospira Inc.

    Infringement of U.S. Patent No. 5,587,497 ("19-nor-Vitamin D Compounds," issued December 24, 1996) following a Paragraph IV certification as part of Hospira's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Abbott's Zemplar® (paricalcitol, used to treat secondary hyperparathyroidism in patients with kidney failure).  View the complaint here.


    Flamel Technologies S.A. v. Anchen Pharmaceuticals, Inc.

    1:11-cv-02570; filed September 9, 2011 in the District Court of Maryland

    Infringement of U.S. Patent No. 6,022,562 ("Medicinal and/or Nutritional Microcapsules for Oral Administration," issued February 8, 2000) following a Paragraph IV certification as part of Anchen's filing of an ANDA to manufacture a generic version of GSK's Coreg® CR (carvedilol, used to treat congestive heart failure).  View the complaint here.


    GlaxoSmithKline LLC v. Mylan Inc. et al.

    1:11-cv-00789; filed September 8, 2011 in the District Court of Delaware

    • Plaintiff:  GlaxoSmithKline LLC
    • Defendants:  Mylan Inc.; Mylan Pharmaceuticals Inc.; Impax Laboratories Inc.

    Infringement of U.S. Patent Nos. 5,565,467 ("Androstenone Derivative," issued October 15, 1996), 5,846,976 (same title, issued December 8, 1998), and 5,998,427 ("Androstenones," issued December 7, 1999) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of GSK's Avodart® (dutasteride, used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate) and GSK's Jalyn® (dutasteride and tamsulosin hydrochloride, used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate).  View the complaint here.


    Cephalon Inc. et al. v. Sandoz Inc.

    1:11-cv-00782; filed September 6, 2011 in the District Court of Delaware

    • Plaintiffs:  Cephalon Inc.; Cephalon France
    • Defendant:  Sandoz Inc.

    Infringement of U.S. Patent No. 7,132,570 ("Method for the Production of Crystalline Forms of Optical Enantiomers of Modafinil," issued November 7, 2006) following a Paragraph IV certification as part of Sandoz's amendment of its ANDA to manufacture a generic version of Cephalon's Nuvigil® (armodafinil, used to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder).  View the complaint here.

  • Calendar

    September 19-20, 2011 – Tech Transfer Summit Europe*** (Tech Transfer Summit Ltd.) – Paris, France

    September 19-21, 2011 – Business of Biosimilars & Biobetters*** (Institute for International Research) – Boston, MA

    September 21-22, 2011 – Forum on European Pharmaceutical Regulatory Law*** (C5) – Brussels, Belgium

    September 22-23, 2011 – FDA Boot Camp*** (American Conference Institute) – Boston, MA

    September 26-27, 2011 – Biosimilars and Biobetters*** (SMi Group) – London, UK

    September 26-27, 2011 – Life Sciences Business Development & Acquisitions in Emerging Markets (American Conference Institute) – New York, NYNew York, NY

    September 28, 2011 – The Impact of Stanford v. Roche on Private Party Transactions:  Inventor Ownership and Government Rights Under Bayh-Dole (American Bar Association) – 1:00 – 2:30 PM (ET)

    September 28, 2011 – USPTO Post-Grant Proceedings After New Patent Reform Law (Strafford) – 1:00 – 2:30 PM (EDT)

    October 3-4, 2011 – Tech Transfer Summit North America*** (Tech Transfer Summit Ltd.) – Bethesda, MD

    October 4-5, 2011 – Maximizing Pharmaceutical Patent Lifecycles*** (ACI) –

    October 5-6, 2011 – Biotech Patenting*** (C5) – London, UK

    October 14, 2011 – Patent Reform: Impact and Strategy for University Research and Tech Transfer (Technology Transfer Tactics) – 1:00 – 5:00 PM (Eastern)

    October 24-26, 2011 – Developing IP Strategies for Crystalline Forms*** (International Quality & Productivity Center) – London, UK

    October 25-26, 2011 – FDA Boot Camp Devices Edition*** (American Conference Institute) – Chicago, IL

    October 25, 2011 – Innovation and Commerce — Global Legal Considerations (U.S. Patent and Trademark Office and Federal Circuit Bar Association) – Tokyo, Japan

    October 26, 2011 – A Discussion with Robert Stoll of the USPTO (Association of Intellectual Property Firms) – 1:00 – 2:00 PM (EDT)

    October 26-27, 2011 – Joint Judicial Conference (U.S. Court of Appeals for the Federal Circuit and Tokyo Intellectual Property High Court) – Tokyo, Japan

    November 9, 2011 – Optimizing Relations with the USPTO: All the Questions You Always Wanted to Ask and Could Never Get Answers For (Association of Intellectual Property Firms) – 12:30 – 1:30 PM (EST)

    November 2-4, 2011 – Biotechnology from the Ground Up (Management Forum and JNB Marketing & Events) – San Diego, CA

    November 30 to December 1, 2011 – Advanced Forum on Biotech Patents*** (American Conference Institute) – Boston, MA

    December 6-7, 2011 – Paragraph IV Disputes*** (American Conference Institute) – San Francisco, CA

    ***Patent Docs is a media partner of this conference or CLE

  • San Francisco #1 American Conference Institute (ACI) will be holding its next Paragraph IV Disputes conference on December 6-7, 2011 in San Francisco, CA.  The conference will allow attendees to:

    • Pinpoint patents that may be vulnerable to a Paragraph IV challenge;
    • Demystify an ANDA applicant's Orange Book strategy and dissecting a challenger's obligations under Paragraph IV;
    • Understand the FTC's current position on pay-for-delay settlements and anticipating any antitrust concerns stemming from agreements between brand names and generics;
    • Master the intricacies of litigation with multiple ANDA filers;
    • Weigh the benefits and risks of an at-risk launch and minimizing downstream risk;
    • Identify the legal and ethical impact that Therasense will have on the affirmative defense of inequitable conduct;
    • Explore the ramifications of increased generic versus generic litigation in the quest for the prize of 180-day exclusivity;
    • Navigate the evolving case law surrounding double patenting obviousness and formulating litigation strategies based on the prior art analysis; and
    • Scrutinize labeling controversies and determining whether a use code expansion is reasonable.

    Brochure In particular, ACI's faculty will offer presentations on the following topics:

    • Pre-suit due diligence strategies: The branded perspective on proactively anticipating Paragraph IV challenges;
    • Certifying under Paragraph IV: Identifying the ANDA applicant's pre-suit considerations and obligations;
    • Let the games begin: The start of the Paragraph IV law suit — Pleadings and considerations;
    • New standards and controversies in double patenting type obviousness: Repercussions for Paragraph IV challenges;
    • No holds barred: Fighting for or defending against the coveted 180 day exclusivity stay;
    • A view from the bench on Paragraph IV litigation;
    • Carve outs and inducement controversies: Examining the intersection between a drug's patent and its label;
    • The post-Therasense world: Pleading and defending against inequitable conduct allegations under the heightened standard for materiality and intent — to be presented in part by Patent Docs author Dr. Donald Zuhn; and
    • Damages and injunctions: Exploring the consequences and conundrums of launching at risk.

    In addition, a pre-conference boot camp entitled "Biosimilars Through the Hatch-Waxman Lens: Anticipating Litigation Challenges and Understanding the Evolving Landscape" will be offered from 1:00 pm to 5:00 pm on December 5, 2011, and a post-conference master class entitled "Settling Paragraph IV Disputes: Drafting and Negotiating Strategies for Brand-names and Generic Companies — A Hands-on, Practical Approach" will be offered from 2:00 pm to 5:00 pm on December 7, 2011.  The master class will offer presentations on the following topics:

    • FTC keynote: Pay for delay settlements — presented by Commissioner J. Thomas Rosch of the Federal Trade Commission; and
    • Obtaining optimal terms and minimizing antitrust concerns when settling Paragraph IV disputes.

    The agenda for the Paragraph IV Disputes conference can be found here.  A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.

    ACI - American Conference Institute The registration fee for the conference is $2,295 (conference alone), $2,895 (conference and either pre-conference boot camp or post-conference master class), or $3,495 (conference, pre-conference boot camp, and post-conference master class).  Those registering by October 12, 2011 will receive a $300 discount and those registering by November 4, 2011 will receive a $200 discount.  In addition, Patent Docs readers who reference the discount code "PD 200" will receive $200 off the current price tier when registering.  Those interested in registering for the conference can do so here, by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.

    Patent Docs is a media partner of the Paragraph IV Disputes conference.

  • Technology Transfer Tactics will be offering a two-part webinar providing "Patent Reform: Impact and Strategy for University Research and Tech Transfer" on October 14, 2011 from 1:00 – 5:00 PM (Eastern).  Charles Macedo of Amster, Rothstein and Ebenstein, LLP; Patent Docs author Dr. Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP; Randi Isaacs, In-House Patent Counsel for Emory University's Office of Technology Transfer; and Brad Brockbank of Segue Consulting will focus on the specifics of the new law and the strategies needed to apply it successfully.  The first session will provide a detailed review of all key provisions and their likely effects and the second session will offer expert guidance on key changes in operations, procedures, and decision-making.

    The registration fee for the webinar is $297 for both sessions or $197 for one session.  Those interested in registering for the webinar, can do so here.

    Technology Transfer Tactics

  • Strafford #1 Strafford will be offering a webinar entitled "USPTO Post-Grant Proceedings After New Patent Reform Law" on September 28, 2011 from 1:00 – 2:30 PM (EDT).  Scott McKeown of Oblon Spivak McClelland Maier & Neustadt and Kevin Laurence of Stoel Rives will provide guidance for counsel to IP owners and inventors on the new America Invents Act's post-grant system, including post-grant review proceedings, special transitional post-grant review of business method patents and supplemental examinations.  The webinar will review the following questions:

    • What are the grounds for post-grant challenges now?
    • How will current reexamination practice change?
    • What are the new options, how will they be implemented, and when?
    • How do the changes of the Leahy-Smith America Invents Act alter the strategic use of post grant proceedings parallel to litigation?
    • What are the relevant deadlines and best practices?

    An interactive Q&A session will follow the presentation.

    The registration fee for the webinar is $297 ($362 for registration and CLE processing).  Those interested in registering for the webinar, can do so here.

  • By Kevin E. Noonan

    Star Scientific The Federal Circuit reaffirmed the primacy of the factual disclosures used to establish obviousness, and how deficiencies thereof can defeat an obviousness claim, in reversing an invalidity determination in Star Scientific, Inc. v. R.J. Reynolds Tobacco Co.  It also showed how persistently defendants pursue the tarnish of inequitable conduct even under circumstances where the Federal Circuit has held that no inequitable conduct occurred.

    The patents-in-suit, U.S. Patent Nos. 6,202,649 and 6,425,401 (filed as a continuation of the '649 patent), were directed to methods for curing tobacco in a way that reduced the amount of a carcinogen, tobacco-specific nitrosamines (TSNAs), in the cured product used in cigarettes and other tobacco-containing products.  The patents were specifically directed to "indirect" flue curing with gas or propane heaters.  Former methods used "direct" flue curing that mixed the exhaust gasses with the tobacco, but this resulted in an oxygen-free environment that fostered the growth of bacteria on the leaves, leading to production by the bacteria of the carcinogenic TSNAs.  The patented methods can be used with either direct or indirect curing methods by using "controlled conditions" involving humidity, temperature, rate of temperature exchange, carbon monoxide levels, carbon dioxide levels, oxygen levels, and how the tobacco plants are arranged in the curing shed.  The claims specify "controlling conditions" by "determining and selecting" the "appropriate" values for these variables that results in the reduction of TSNA production "at least one").  However, the patents admit that the choice of these conditions are "more art than science," so need to choose the appropriate combination of these variables; however, the important consideration is maintaining an aerobic environment that prevents bacterial growth.

    Claims 4 and 12 of the '649 patents are set forth for the Court as being representative (emphasis in the opinion):

    4.  A process of substantially preventing the formation of at least one nitrosamine in a harvested tobacco plant, the process comprising:
        drying at least a portion of the plant, while said portion is uncured, yellow, and in a state susceptible to having the formation of nitrosamines arrested, in a controlled environment and for a time sufficient to substantially prevent the formation of said at least one nitrosamine;
        wherein said controlled environment comprises air free of combustion exhaust gases and an airflow sufficient to substantially prevent an anaerobic condition around the vicinity of said plant portion; and
        wherein said controlled environment is provided by controlling at least one of humidity, temperature, and airflow.

    12.  The process according to claim 4, wherein the treatment time is from about 48 hours up to about 2 weeks.

    The lawsuit arose after R.J. Reynolds (RJR) acquired previous licensee Brown and Williamson and terminated the license.  In addition, RJR has its own patents (referenced in the opinion as the Peele reference), issued as U.S. Patent No. 6,805,134 that specified a "not direct" heat source and curing in the absence of nitrocv oxide gas, which was performed by retrofitting direct cure barns into indirect-cure barns.

    As an initial matter, the District Court granted summary judgment that the '649 and '401 patents were not entitled to priority to a provisional application, based on disclosure in the provisional that the claimed methods utilized an air flow of "at least 28,000 cubic feet per meter (CFM)" whereas the common specification of the '649 and '401 patents specified an air flow of "approximately 25,000 CFM."  As a consequence, the District Court was able to consider intervening art to be prior art, and to decide that the patentee did not disclose the best mode (based on development of the commercial embodiment (and acknowledged best mode) in the period between the provisional and non-provisional filing dates.

    In an earlier decision, the Federal Circuit reversed a finding that the claims were indefinite for reciting the term "anaerobic condition" and reversed a finding of inequitable conduct for failure to disclose a purported prior art reference (termed the "Burton letter").  Despite this decision, the District Court permitted defendants to display a slide (below) during closing argument showing a shadowy person disclosing information to the PTO examiner but holding the disputed Burton letter reference behind his back, during part of closing argument relating to invalidity rather than inequitable conduct.

    Burton Slide
    The jury delivered a verdict of non-infringement and invalidity based on obviousness, anticipation, indefiniteness, and failure to disclose the best mode.  The obviousness determination was based on a prior art scientific journal review relating to methods for air curing and a published Japanese patent.  In view of the District Court's decision on the priority question, the jury applied the method disclosed in the Peele '134 patent as well as the practice of methods at two farms (Spindletop and the Brown farm) as a public use (the Brown tobacco farm being under contract to RJR).  The indefiniteness determination was directed at the term "controlled environment," which the Court found as a matter of law was incapable of being construed because the disclosed "controlled environment" conditions overlapped with "conventional" curing conditions so that the skilled worker could not understand the difference.  The best mode determination was based squarely on the District Court's priority determination, since it was uncontested that the best mode commercial embodiment was not disclosed and had been developed prior to the non-provisional filing dates.  Finally, the jury found that there was no infringement, based on oxygen levels in RJR's barns alleged to be infringing.  The District Court denied Star's motions for JMOL of these adverse decisions.

    Federal Circuit Seal The Federal Circuit, in an opinion by Chief Judge Rader, joined by Judge Linn and by Judge Dyk in part, who dissented as to the Court's decision to reverse invalidation for indefiniteness, reversed the District Court's grounds for invalidating the '649 and '401 patents, and affirmed the District Court's denial of JMOL on the jury's non-infringement decision.  The Federal Circuit also reversed the finding that the '649 and '401 patents were not entitled to the provisional filing date, on the basis that the specification satisfied the priority standard:  that the specification disclosed an adequate written description and enabled the patents' claims.

    This part of the opinion was supported by an intervening decision by the USPTO in a reexamination of the '649 and '401 patents that these patents were entitled to the priority date (although the PTO found certain of the claims were invalid for obviousness).  The Court based its decision on language in the provisional specification that the recited air flow speed (in CFM) could "vary according to conditions and may be determined on a routine basis," and thus held that the District Court had improperly narrowed the claim scope based on later examples in the non-provisional application.

    As a consequence of the Court granting the priority date of the provisional application to the '649 and '401 patents the best mode violation evaporated, since it was equally undisputed that the commercial method was not known at the time the provisional application was filed.  Another consequence, germane to anticipation and obviousness is that the Peele '134 patent was not prior art that could be asserted against the patents in suit.

    In reversing the District Court's indefiniteness determination, the majority opinion cites Datamize LLC v. Plumtree Software Inc. for the standard that a claim must be "insolubly ambiguous" or "not amenable to construction" to be found indefinite.  However, the majority cautioned that "[a]bsolute clarity [is] not required" and that the term at issue — "controlled environment" — does not require disclosure of exact values for the various parameters because the skilled worker would understand the variable and empirical nature of determining these conditions.  In this the opinion cites language from the Peele '134 patent — owned by RJR — consistent with its interpretation of the understanding of the worker skilled in the art.

    Regaring obviousness, the Court disagreed with jury verdict that the references render the claims obvious.  The opinion characterized the Japanese patent as being directed at improving fast curing to avoid "nasty odor" (an advantage not related to TSNA production) and found the Wiernik reference to be inconclusive on whether bacteria were involved in TSNA production.  In addition, the opinion notes that neither reference discusses exhaust gases or anaerobic conditions.  Thus, the Court found that there would be no motivation (or in the mantra approved by the KSR Court, "reasoned basis") for the skilled worker to combine these references to arrive at a solution to the problem of TNSA production during tobacco curing.  The Court also found significant evidence of secondary considerations, including:  a recognized, unmet need in the art for reducing TSNA in cured tobacco; unsuccessful attempts (i.e., failure) by others to solve this recognized problem; purported unexpected results (never expressly set forth in the opinion); and commercial success (ironically for RJR, using the lucrative B&W licenses as evidence thereof).

    The Court reversed the jury's anticipation finding as to the Peele method because it was no longer prior art in view of the earlier priority date.  The two "public uses" were not prior art, because the Court found that the "Spindletop" use involved tobacco cured before treatment in the drying shed (so that it was not "uncured" tobacco, as required by the claims).  The "Brown farm" use did not anticipate, according to the Court's opinion, because the reported test results were below the detection threshold for TNSAs and thus provided no evidence that this method satisfied the specifically recited range of TSNA reduction required by the claims.

    Finally, the Court upheld the non-infringement decision based on the jury's prerogative to believe one (RJR's) expert over another (Star's), and that the evidence did not establish that no reasonable jury could come to such a decision (i.e., the District Court properly denied Star's JMOL motion).

    The Court also refused to deny Star's appeal on evidentiary rulings permitting (inter alia) display of the "shadowy figure" slide (although the Court found its use "troubling"), because Star did not show harm resulting from the objectionable evidence.

    Judge Dyk dissents in part, arguing that the patents are invalid for indefiniteness — in his view, the specification did not sufficiently distinguish the "controlled" conditions from "conventional" conditions and thus did not "particularly point out and distinctly claim" the invention so that the skilled worker could not ascertain the metes and bounds of infringing behavior.

    Star Scientific, Inc. v. R.J. Reynolds Tobacco Co. (Federal Circuit 2011)
    Panel: Chief Judge Rader and Circuit Judges Linn and Dyk
    Opinion by Chief Judge Rader; opinion concurring-in-part and dissenting-in-part by Circuit Judge Dyk

  • By Kevin E. Noonan

    ACLU Yesterday, the Federal Circuit denied Plaintiffs' petition for panel rehearing in Association for Molecular Pathology v. U.S. Patent and Trademark Office.  In their petition, counsel for Plaintiffs/Appellees asserted two grounds for rehearing, of points of law and fact overlooked or apprehended by the Court (see "Plaintiff(s) File Petition for Rehearing in AMP v. USPTO").  First, the petition contended that the Court "failed to consider whether the DNA fragments claimed in these patents are products of nature."  Second, the Court was alleged to have erred by not finding that two other named Plaintiffs, the American College of Medical Genetics and specifically named plaintiff Ellen Matloff, satisfied the standards for standing enunciated by the Court.

    Myriad The Court did not address Defendants' petition for panel rehearing.  That petition asked the Court to review the standing issue based on their allegation that Dr. Harry Ostrer, the only plaintiff found to have standing, no longer has the capacity for "immediately begin[ning] to perform BRCA 1/2-related genetic testing" upon invalidation of the Myriad patents.

    The one certain consequence of the filing of Plaintiffs' petition is that any petition for certiorari will be delayed, making it likely that the Supreme Court will decide the Prometheus Laboratories, Inc. v. Mayo Collaborative Services case before reaching the invalidated method claims in Myriad.

    For additional information regarding this and other related topics, please see:

    • "Defendants File Petition for Rehearing in AMP v. USPTO," August 30, 2011
    • "Plaintiff(s) File Petition for Rehearing in AMP v. USPTO — Update," August 29, 2011
    • "Plaintiff(s) File Petition for Rehearing in AMP v. USPTO," August 28, 2011
    • "CyberSource and the Tragedy of Bad Analogies," August 24, 2011
    • "Is Claim Construction the Key to Patent-eligibility of Isolated DNA?" August 23, 2011
    * "WFU Law Professor Says Federal Circuit Failed as "Keeper of the Constitution" in AMP v. USPTO," August 22, 2011
    • "AMP v. USPTO: Standing," August 4, 2011
    • "AMP v. USPTO: Judge Bryson's Opinion," August 3, 2011
    • "AMP v. USPTO: Judge Moore's Concurring Opinion," August 2, 2011
    • "Association for Molecular Pathology v. United States Patent and Trademark Office (Fed. Cir. 2011)," August 1, 2011
    • "Standing in AMP v. USPTO: The Plot Thickens," July 29, 2011
    • "Federal Circuit Issues Decision in AMP v. USPTO," July 29, 2011
    • "Myriad Writes to Federal Circuit on Standing Issue," July 28, 2011
    • "AMP v. USPTO: Oral Argument at the Federal Circuit," April 4, 2011
    • "Federal Circuit to Hear Argument in AMP v. USPTO," April 3, 2011
    • "Curiouser and Curiouser," February 16, 2011
    • "AMP v. USPTO — Briefing Update III," February 8, 2011
    • "Amicus Briefs in AMP v. USPTO: AARP," January 27, 2011
    • "AMP v. USPTO: Appellees' Brief," January 12, 2011
    • "AMP v. USPTO — Briefing Update II," December 16, 2010
    • "Amicus Briefs in AMP v. USPTO: Alynylam Pharmaceuticals, Inc.," December 15, 2010
    • "The Relevance of Patent Exhaustion in the Myriad Genetics Case," December 14, 2010
    • "AMP v. USPTO — Briefing Update," December 14, 2010
    • "Amicus Briefs in AMP v. USPTO: University of New Hampshire School of Law," December 12, 2010
    • "Amicus Briefs in AMP v. USPTO: Rosetta Genomics & George Mason University," December 8, 2010
    • "Academic Amici Refute ACLU Falsehoods in Gene Patenting Debate," December 7, 2010
    • "Amicus Briefs in AMP v. USPTO: Genetic Alliance," November 10, 2010
    • "BIO and AUTM File Joint Amicus Brief in AMP v. USPTO," November 9, 2010
    • "AIPLA Submits Amicus Brief in AMP v. USPTO," November 3, 2010
    • "IPO Files Amicus Brief in AMP v. USPTO," November 2, 2010
    • "AMP v. USPTO — Briefing Update," November 1, 2010
    • "DOJ Tries to Be All Things to All Constituencies in Myriad Amicus Brief," October 31, 2010
    • "Myriad Files Appeal Brief in AMP v. USPTO," October 28, 2010
    • "AMP v. USPTO — Briefing Schedule Update," August 22, 2010
    • "FCBA Submits Amicus Brief on Motion for Recusal in AMP v. USPTO," August 9, 2010
    • "Appellees Move for Recusal of Chief Judge Rader in AMP v. USPTO Appeal," July 19, 2010
    • "AMP v. USPTO after Bilski v. Kappos," July 6, 2010
    • "Myriad Appeals AMP v. USPTO Decision," June 16, 2010
    • "AMP v. USPTO: What Everyone Else Is Saying – Part II," June 8, 2010
    • "AMP v. USPTO: What Everyone Else Is Saying," April 6, 2010
    • "'60 Minutes' and 'Newshour' Take Different Approaches to Covering Gene Patenting Story," April 5, 2010
    • "'60 Minutes' Examines Gene Patenting Issue on Sunday, April 4th — Patent Docs Author Kevin Noonan to Appear on Program," April 2, 2010
    • "AMP v. USPTO: What the Parties Are Saying About the Decision," April 1, 2010
    • "Caught in a Time Warp: The (In)validity of BRCA1 Oligonucleotide Claims," March 30, 2010
    • "Round One Goes to the ACLU," March 29, 2010
    • "USPTO Asks out of Gene Patenting Case (Again)," January 19, 2010

  • By Donald Zuhn

    Earlier this year, the Intellectual Property Owners Association (IPO) released its 28th annual list of the top 300 organizations receiving U.S. patents.  As in past years, Patent Docs used the IPO's list of top patent holders to compile a list of the top "biotech and pharma" companies and organizations receiving U.S. patents in 2010 (see "IPO Releases List of Top 300 Patent Holders for 2010").  As noted in the IPO's Top 300 list, 207,915 patents were issued in 2010, which constituted a 25.8% increase over the 165,213 patents that issued in 2009.  The outlook was even brighter for the biotech/pharma industry, as 14,786 biotech/pharma patents were issued in 2010, which constituted a 38.9% increase over the 10,644 biotech/pharma patents that issued in 2009.

    This increase in biotech/pharma patents is shown in the chart below, which also shows the number of biotech/pharma patents that issued between 2001 and 2011 (blue bars, left axis) and the number of biotech/pharma applications that published (red line, right axis) over this same time frame (note: figures for 2011 are projected based on issuances and publications through August 31).

    Patents & Publications
    In the chart above, the blue bars represent the number of patents designated as belonging to classes 424 (Drug, Bio-Affecting and Body Treating Compositions), 435 (Chemistry: Molecular Biology and Microbiology), 436 (Chemistry: Analytical and Immunological Testing), 504 (Plant Protecting and Regulating Compositions), 506 (Combinatorial Chemistry Technology: Method, Library, Apparatus), and/or 514 (Drug, Bio-Affecting and Body Treating Compositions) that issued in the specified year.  The red line represents the number of patent applications designated as belonging to one of the above classes that published in the specified year (because the AIPA mandated publication of certain U.S. applications filed after November 28, 2000, only 3,920 biotech/pharma applications were published in 2001).

    If the numbers through the end of August hold up during the remainder of the year, biotech/pharma patent issuances will rise to 14,889 in 2011, but published biotech/pharma applications will drop from 33,145 in 2010 to 30,582 (which would be the first drop in published biotech/pharma applications since 2007).

  • By Donald Zuhn

    Senate Seal With the eighth round of negotiations of the Trans-Pacific Partnership (TPP) agreement currently underway in Chicago, a number of Senators have written to the U.S. Trade Representative, Ambassador Ron Kirk, to push for the inclusion of intellectual property provisions that are consistent with U.S. biologics exclusivity standards (i.e., 12 years of data exclusivity).  The TTP, or Trans-Pacific Strategic Economic Partnership Agreement, is a multilateral free trade agreement currently being negotiated by Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the United States, and Vietnam.

    In a letter sent today by Senators Mark Udall (D-CO) and Michael Bennet (D-CO), the Colorado legislators "stress the importance of proposing a high standard of intellectual property rights for biologics, which is consistent with the 12 years of exclusivity under U.S. law."  The letter states that "[b]eginning the biologics negotiations on an intellectual property standard consistent with U.S. law will make sure that Coloradans can continue to lead the world in the innovation of biologics while also assuring a reasonable pathway for biosimilar products."  The Senators conclude their letter by stating that "[a]s we continue to look towards the inclusion of clear and enforceable intellectual property rights in the TPP Agreement, we hope that the Office of the U.S. Trade Representative finalizes its negotiations in a manner that reflects U.S. law on biologics exclusivity standards."

    U.S. Trade Representative In a second letter sent today, 37 Senators, led by Senators Orrin Hatch and John Kerry, state that "[w]hile the views of individual members of Congress may differ as to the desirability of [the TPP] negotiations, we are united in urging you to propose a strong minimum term of regulatory data protection for biologics consistent with U.S. law."  Noting that "U.S. law provides for a 12-year term of regulatory data protection for biologics," the group declares that this 12-year period "should serve as the baseline for the administration's objectives for this aspect of the negotiation."  The legislators point out that "[t]his 12-year term was the result of careful deliberations in which the U.S. Congress arrived at a bipartisan consensus taking into account and weighing many factors," and contends that "the agreed upon term of protection best supports the Congress' goals of maintaining the nation's competitiveness as the leading innovator of biologics products, increasing the number of high-value jobs, and improving access to safe and affordable medicines by creating a clear pathway for the regulatory approval of biosimilar drugs."

    The letters sent to Ambassador Kirk today follow two letters sent to President Obama by several House members over the summer.  In one letter, sent by Rep. Henry Waxman (D-CA), Jim McDermott (D-WA), Fortney Pete Stark (D-CA), Rosa DeLauro (D-CT), Janice Schakowsky (D-IL), Peter Welch (D-VT), and Raul Grijalva (D-AZ), the House legislators "strongly recommend[ed]" that President Obama seek to exclude the 12-year data exclusivity period provided by the biosimilar approval pathway of the Patient Protection and Affordable Care Act (PPACA) from the intellectual property provisions of the Trans-Pacific Partnership (TPP) agreement (see "House Legislators Lobby to Exclude 12-Year Data Exclusivity Period from Free Trade Agreement").  In a letter sent one week earlier than the Waxman letter, a bipartisan group of forty Representatives sent their own letter to the President, indicating their support for the President's "continued efforts to ensure that intellectual property standards in the Trans-Pacific Partnership ("TPP") trade agreement are consistent with U.S. law, protect U.S. interests and sustain and help grow U.S. jobs" (i.e., in support of the 12-year exclusivity period) (see "Legislators Urge President to Include 12-Year Data Exclusivity Period in Free Trade Agreement").

    After the round of negotiations in Chicago concludes, TPP members are scheduled to meet in Peru in October.  The nine TPP members have set a goal of reaching the outlines of an agreement by November of this year.

  • By Donald Zuhn

    On Thursday, the Senate passed the House version of the Leahy-Smith America Invents Act (H.R. 1249) by an 89-9 vote (see "Senate Passes H.R. 1249").  The legislation now awaits the President's signature before becoming law.  That signing could come as early as Monday, after the President spent Friday morning and early afternoon in Richmond, VA discussing his jobs creation plan, and Sunday attending September 11 10th Anniversary Commemoration Ceremonies in New York, Shanksville, PA, and the Pentagon.  While the patent community awaits the bill's signing, a number of organizations and trade groups have issued statements regarding the Senate's passage of H.R. 1249.

    Biotechnology Industry Organization (BIO) In a statement issued by the Biotechnology Industry Organization (BIO), the group "applaud[ed] the Senate's passage of The Leahy-Smith America Invents Act as it marks the conclusion of a long and vigorous debate on how to best modernize our nation's patent system."  BIO stated that "[t]he improvements made by the bill will benefit all sectors of the national economy by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system."  Noting that "[s]trong intellectual property protection is critical for [small biotech] companies," the biotech industry group contended that such companies would "benefit from the improvements to our nation's patent system made by this legislation.  While commending Senate Judiciary Chairman Patrick Leahy (D-VT) and Ranking Member Charles Grassley (R-IA) as well as House Judiciary Chairman Lamar Smith (R-TX) and Ranking Member John Conyers (D-MI) "for their tireless efforts over the past several years," and noting that the group was "pleased that this bill is now headed to President Obama for his signature," BIO also "urge[d] the Congress to fulfill its commitments as part of this bill to end fee diversion at the U.S. Patent and Trademark Office (USPTO) once and for all."

    Innovation Alliance The Innovation Alliance released a statement in which the group commended Chairman Leahy, Ranking Member Grassley, Chairman Smith, Ranking Member Conyers, House Subcommittee on Intellectual Property, Competition, and the Internet Chairman Bob Goodlatte (R-VA) and Ranking Member Melvin Watt (D-NC), Senators Jon Kyl (R-AZ), Dianne Feinstein (D-CA), Tom Coburn (R-OK), "and other congressional leaders too numerous to list . . . for their leadership and unwavering commitment to trying to get the policy right."  However, the Innovation Alliance expressed its "regrets that the Act does not end once and for all the diversion of patent office user fees for general federal government purposes," noting that "[e]nding fee diversion is the one issue in this debate that has united all patent stakeholders and most policymakers."  The group "believe[s] that as long as the possibility of fee diversion continues, the United States Patent and Trademark Office (USPTO) cannot reliably make multi-year plans, hire and retain personnel, and improve operations and information technology, all of which are critical to processing the nearly 700,000 patents in the backlog of pending patent applications," adding that "[d]elayed patent issuance is tantamount to foregone innovation and unrealized American jobs."  Despite the now likely enactment of the Leahy-Smith America Invents Act, the Innovation Alliance stated that it "remains committed to continuing our efforts in conjunction with other patent stakeholders to ensure that the USPTO retains all of the user fees it earns."  According to the Innovation Alliance website, the group "represents innovators, patent owners and stakeholders from a diverse range of industries that believe in the critical importance of maintaining a strong patent system that supports innovative enterprises of all sizes."

    Coalition for 21st Century Patent Reform The Coalition for 21st Century Patent Reform opened its statement by suggesting that "after six years of hard work and debate in both the House and Senate, [the Senate's passage of H.R 1249 was] the last legislative step necessary for significantly strengthening the U.S. patent system for all American inventors."  The group contended that "[t]he Leahy-Smith America Invents Act gives our nation a modern, world-class patent system that allows innovation to flourish and create new industries that will add thousands of well-paying jobs for American workers," adding that the "landmark bill . . . will encourage American innovation for years to come."  Stating that the legislation "provides a package of clearly needed improvements to our patent system that will help innovators compete in today's global marketplace," the Coalition stated that "[i]nventors and patent applicants will have a simpler, more transparent and objective path to patent protection," and "[a]t the same time, [will] benefit from a reduction in the time, costs and unpredictability associated with the current system."  The group concluded by noting that it "will closely monitor the new Patent and Trademark Fee Reserve Fund to ensure that all patent fees remain within the Patent and Trademark Office and are promptly available to serve the needs of inventors and the public."

    Coalition for Patent Fairness #1 In a short statement issued by the Coalition for Patent Fairness, the group (which members include Adobe, Apple, Cisco, Dell, Google, Intel, Intuit, Micron, Oracle, RIM, SAP, and Symantec) "congratulate[d] Chairman Leahy, Chairman Smith, and additional key Members of Congress on the passage of H.R. 1249, the Leahy-Smith America Invents Act," and "applaud[ed] the House and the Senate for passing a bill that takes significant steps toward strengthening America's patent system and promoting innovation."  Noting that the Senate's passage of H.R. 1249 "marks the end of more than six years of debate and represents a consensus amongst many critical stakeholders," the CPF declared that "[t]he bill contains critical provisions that will advance and harmonize our patent system, while making the U.S. more competitive in the international marketplace."